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Summary 
Vetsuisse Faculty, University of Zurich 2015 
Anna Sophie Ramsauer 
Institute of Virology, email@vetvir.uzh.ch 
and 
Clinic for Small Animal Internal Medicine, Dermatology, sekretariat@kltmed.ch 
 
Viral and cellular transcription profiles in Equine Papillomavirus Type 2 
positive squamous cell carcinomas  
 
Among the different equine papillomaviruses (EcPV), EcPV type 2 seems to have the 
most important clinical impact on horses, since it appears to be a causal factor for the 
development of penile squamous cell carcinomas (SCC). Unfortunately, the 
pathomechanisms associated with this cancer transformation are not known, yet.  
To address this issue, penile tissue samples were collected from five horses with 
EcPV2-positive SCC as well as from three healthy EcPV2-negative horses. Thereof 
transcriptome analysis of the viral and the host genome was performed. 
Indeed, EcPV2 was transcriptionally active in all the SCC samples, whereas EcPV2 
mRNA was not detected in any control tissues. While only few reads mapped to the 
structural viral genes, up to some thousands reads mapped to the non-structural 
early (E) genes, in particular to E2, E4, E6 and E7. Within these reads a distinct 
pattern of splicing events was observed, while most abundant splice junctions were 
E1^E4 and E1^E2. Host genes, differentially expressed between SCC and control 
samples, were most abundantly related to cell cycle, RNA processing and focal 
adhesion. A comparison of our findings with published results suggested that Matrix 
Metalloproteinase 1 (MMP1) and Interleukin 8 (IL8) may represent potential marker 
genes for the development of SCCs in EcPV2 associated lesions. 
Consequently, further research on EcPV2-related pathomechanisms may focus on 
the viral genes E2, E4, E6 and E7 and the cellular genes MMP1 and IL8. 
 
Keywords: horse, papillomavirus, EcPV2, penile carcinoma, transcriptome 
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Zusammenfassung 
Vetsuisse-Fakultät Universität Zürich 2015 
Anna Sophie Ramsauer 
Virologisches Institut, email@vetvir.uzh.ch 
und 
Klinik für Kleintiermedizin, Dermatologie, sekretariat@kltmed.ch 
 
Virales und zelluläres Transkriptionsprofil von 
 Equines-Papillomavirus-Typ-2-positiven Plattenepithelkarzinomen 
 
Unter den verschiedenen equinen Papillomaviren (EcPV) scheint EcPV Typ 2 die 
größte klinische Relevanz beim Pferd zu haben, da es offenbar ein entscheidender 
Faktor für die Entwicklung von Plattenepithelkarzinomen (PEK) am Penis ist. 
Allerdings sind die genauen Pathomechanismen dieser Krebstransformation leider 
noch nicht bekannt. 
Daher wurden Gewebeproben vom Penis von fünf Pferden mit EcPV2-positiven 
PEKs, sowie von drei gesunden EcPV2-negativen Pferden gesammelt. Davon 
wurden Transkriptom-Analysen des Virus- und des Wirtsgenom durchgeführt. 
Transkripte von EcPV2 konnten in allen PEK Proben nachgewiesen werden, jedoch 
nicht in den Kontroll-Proben. Während die viralen Strukturgene nur spärlich von der 
Sequenzinformation abgedeckt wurden, ließen sich mehrere tausend Sequenzstücke 
den Nichtstrukturgenen (E), vor allem E2, E4, E6 und E7, zuordnen. Dort konnten 
außerdem Spleißverbindungen detektiert werden, wobei E1^E4 und E1^E2 die 
häufigsten waren. Die Wirtsgene, die zwischen PEKs und Kontrollproben 
unterschiedlich exprimiert waren, stehen vor allem in Zusammenhang mit Zellzyklus, 
RNA-Prozessierung und fokaler Adhäsion. Vergleiche mit anderen Studien zeigten, 
dass Matrix Metalloproteinase 1 (MMP1) und Interleukin 8 (IL8) als Markergene für 
die Entstehung von PEKs in EcPV2 assoziierten Veränderungen dienen könnten. 
Daher möge sich die weitere Erforschung der EcPV2 assoziierten 
Pathomechanismen auf die viralen Gene E2, E4, E6 und E7 und die zellulären Gene 
MMP1 und IL8 fokussieren. 
 
Stichworte: Pferd, Papillomavirus, EcPV2, Peniskarzinom, Transkriptom 
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Abbreviations 
 
BPV bovine papillomavirus 
CDK   cyclin dependent protein kinase 
CIN  cervical intraepithelial neoplasia 
CXCL8   chemokine (CXC motif) ligand 8 
DE   differently expressed  
E  early gene (papillomavirus) 
EcPV equine papillomavirus 
fc  fold change 
FDR  false discovery rate  
GEO   Gene Expression Omnibus  
GO term BP  Gene Ontology term biological processes 
HPV human papillomavirus 
IL8   Interleukin 8  
KEGG   Kyoto Encyclopedia of Genes and Genomes  
L  late gene (papillomavirus) 
LCR  long control region 
MMP1  Matrix Metalloproteinase 1  
NCBI  National Center for Biotechnology Information  
ORF  open reading frames  
PEK  Plattenepithelkarzinom 
PV papillomavirus  
RIN  RNA integrity number 
SCC squamous cell carcinoma 
TMM  trimmed means of M values 
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1. Introduction 
1.1. Papillomavirus 
Papillomaviruses (PV) are non-enveloped highly species-specific epitheliotropic DNA 
viruses (Howley PM, Lowy DR et al. 1990). After infection of keratinocytes in the 
basal layer of stratified squamous epithelia, they replicate in the nucleus in a 
differentiation-dependent manner (Zheng, Baker 2006). They can induce benign 
lesions of the skin and mucous membranes, like warts and condylomas in many 
species. Some PVs are also involved in the development of malignant epithelial 
lesions like squamous cell carcinomas (SCCs) (Howley PM, Lowy DR et al. 1990). 
The cancer-associated human papillomaviruses (HPV) are classified as high-risk 
HPV types, while the other HPVs are divided into intermediate or low risk types 
depending on the frequency with which they are found in cancers (Doorbar 2006). 
The PV particles are about 55 nm in diameter and consist of a single molecule of 
double-stranded circular DNA, surrounded by a capsid. The viral genome, which is 
approximately 8000 base pairs in size, contains up to ten open reading frames 
(ORFs) and a long control region (LCR). The ORFs are classified as early genes (E), 
which encode for viral proteins involved in the regulation of replication and synthesis 
of viral DNA, and late genes (L), which encode for the structural capsid proteins 
(Howley PM, Lowy DR et al. 1990). Usually the viral gene expression leads to the 
expression of up to six non-structural viral regulatory proteins (E1, E2, E4, E5, E6 
and E7) in undifferentiated or intermediately differentiated keratinocytes and two 
structural viral capsid proteins (L1 and L2) in keratinocytes undergoing terminal 
differentiation (Zheng, Baker 2006).  
The viral gene expression is tightly regulated at transcriptional and post-
transcriptional levels depending on the cell differentiation in the infected cells (Zheng, 
Baker 2006). In general, transcription of PV starts at either of two main promoter and 
end at either of two poly(A) sites revealing two main polycistronic pre-mRNA species. 
Through extensive use of alternative splicing PVs have the ability to produce a 
variety of products from the same genomic sequences from their compact genomes 
and to individually regulate expression of each gene during the viral life cycle 
(Schwartz 2013). 
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After infection of keratinocytes in the basal layer, the virus expresses E1 and E2 
proteins, which are needed for replicating and maintaining the viral DNA and the 
regulation of early transcription. The E4 protein continues to be expressed in the 
terminally differentiated keratinocytes and is associated with cytokeratin filament 
collapse. E5, E6, and E7 are viral oncogenes, however not all PVs encode for an E5 
protein. They induce cell immortalization and transformation. In particular the viral 
oncoproteins E6 and E7 stimulate cell growth by inactivating the cellular tumour 
suppressor proteins p53 and pRb. The late genes L1 and L2 are needed to assemble 
the capsids in the upper layers (Doorbar 2005; Zheng, Baker 2006). 
The lifecycle of PV depends on epithelial differentiation. The viral genomes are 
maintained as episomes in the basal layer and the viral gene expression is closely 
regulated by the migration of infected cells towards the epithelial surface. However, in 
some high-risk PVs the viral gene expression becomes deregulated and the normal 
life cycle of the virus cannot be completed (abortive infection). The dysregulation 
might be correlated with loss of E2 gene due to integration of the genome into the 
host genome. Such abortive infections can predispose to cancer, as with other DNA 
tumour viruses. The cancer develops in individuals who fail to resolve their infection 
and retain oncogene expression for years or decades. Though, in most individuals, 
immune regression leads to clearance or maintenance in a latent or asymptomatic 
state in the basal cells (Doorbar 2005, 2006). 
1.2. Papillomavirus in horses 
Seven different equine papillomaviruses (EcPV1-7) and three bovine 
papillomaviruses (BPV1, BPV2 and BPV13) are described to infect horses (Lange et 
al. 2013b; Scott, Miller 2011; Lange et al. 2011; Ghim et al. 2004; Lunardi et al. 
2013). The bovine papillomaviruses are associated with the equine sarcoid and 
induce fibropapillomas (Scott, Miller 2011; Lunardi et al. 2013; Howley PM, Lowy DR 
et al. 1990). EcPV1 causes the so called classical equine viral papillomas, which 
occur mainly on the muzzle or lips and are typically found in young horses (Scott, 
Miller 2011). EcPV2 was detected in penile papillomas and SCC, while EcPV3 seems 
to be associated with aural papillomas and plaques (Lange et al. 2011). Yet, there is 
not much known about the other EcPVs, though they were also detected in genital 
plaques (EcPV4), aural plaques (EcPV5, EcPV6) or penile masses (EcPV7) (Lange 
et al. 2013b). Within the different equine papillomaviruses, EcPV2 seems to have the 
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most important clinical impact on horses, since it appears to be a causal factor for the 
development of penile squamous cell carcinomas (Bogaert et al. 2012; Knight et al. 
2011; Lange et al. 2011; Lange et al. 2013a; Scase et al. 2010; Sykora et al. 2012). 
1.3. Equine penile squamous cell carcinoma 
SCC is a malignant neoplasm arising from keratinocytes. It occurs preferentially at 
mucocutaneous junctions, most frequently at the external genitalia and the ocular 
region in horses (Scott, Miller 2011). Penile and preputial tumours are not uncommon 
in horses. Several tumour types have been described at the external genitalia of 
horses, but SCC represents the most frequent genital neoplasm. Penile SCCs are 
mainly detected on the glans penis (Van Den Top, J G B et al. 2008). Early clinical, 
stages present as grey small papules while advanced cases may develop more 
proliferative or ulcerated lesions (Lange et al. 2013a). Genital SCCs pose a 
significant welfare problem to the affected horses, because aggressive and often 
repeated surgical therapy is required to manage the lesions. In most cases 
phallectomy is the treatment of choice (Mair et al. 2000). The prevalence of SCC is 
significantly higher in geldings, light pigmented breeds and also increases with the 
age (Scott, Miller 2011). The aetiology of penile SCC in horses has not completely 
been investigated so far, but there is strong evidence that EcPV2 seems to be 
involved in the development of those lesions (Scase et al. 2010; Lange et al. 2013a; 
Bogaert et al. 2012; Knight et al. 2011; Sykora et al. 2012; Lange et al. 2011). 
1.4. EcPV2 
EcPV2 was first described only a few years ago. Two closely related sequence 
variants of this virus were published in 2010 and 2011 (Scase et al. 2010; Lange et 
al. 2011). The EcPV2 genome consists of 7803 basepairs and contains 7 ORFs, a 
large and a small non-coding region (Scase et al. 2010; Lange et al. 2011). The 
ORFs encode for five early PV viral genes E6, E7, E1, E2 and E4 and two late 
structural viral genes L2 and L1 (Scase et al. 2010; Lange et al. 2011). Since the first 
description of the virus, EcPV2 DNA was consistently detected in equine penile 
papillomas and in situ and invasive SCCs (Bogaert et al. 2012; Knight et al. 2011; 
Lange et al. 2011; Lange et al. 2013a; Scase et al. 2010; Sykora et al. 2012). 
However, EcPV2 DNA was also detected in the mucosa of healthy horses. The 
prevalence for EcPV2 differs depending on the different studies between 2.6% and 
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18% (Fischer et al. 2014; Sykora et al. 2012; Bogaert et al. 2012; Knight et al. 2011; 
Knight et al. 2013). In Switzerland more than one third of the healthy horses have 
antibodies against EcPV2. Possibly EcPV2 is a prevalent virus circulating among the 
equine population and other cofactors, similar to the situation during HPV infections, 
could be involved in the development of SCCs (Fischer et al. 2014). Nevertheless 
EcPV2 is significantly more frequently detected in penile SCCs than in non-
cancerous tissues and also shows higher viral loads in SCCs (Knight et al. 2013). 
Viral mRNA, which suggests an active pathogenic role of the virus or the viral 
proteins in the formation of SCCs could be shown in these lesions (Sykora et al. 
2012). Yet, there is not much known, about the relationship between tumour 
characteristics and prognosis (Van den Top, J. G. B. et al. 2014). In human penile 
carcinomas the presence of high-risk human papillomavirus DNA predicts favourable 
outcome in survival (Lont et al. 2006). Also the nuclear proteins tumour protein p53 
and proliferation marker Ki67 seem to be correlated to nodal metastasis and are 
suggested as prognostic markers in human penile cancer (Muneer et al. 2009; 
Protzel et al. 2007). However, neither p53 and Ki67 nor the presence of EcPV2 or the 
expression of the viral genes (E2, E6 and E1) seem to be good prognosticators for 
equine penile SCCs (Van den Top, J. G. B. et al. 2014). Until now there is a lack of 
knowledge about good prognosticators and the mechanisms driving this disease 
associated with this prevalent virus. Therefore it might be important to unravel the 
pathomechanisms associated with the cancer transformation and to identify genes 
which could be useful as biomarkers for the development and prognosis of EcPV2 
associated SCC. 
1.5. RNA-Seq 
RNA-Seq is a recently developed approach, which allows transcriptome profiling of 
genomes at a high resolution (Nagalakshmi et al. 2010; Wang et al. 2009). 
Complementary DNAs (cDNAs) generated from the RNA pool of interest are directly 
sequenced using deep sequencing technologies. By aligning the obtained millions of 
reads to a reference genome a transcriptome map can be constructed. Furthermore, 
counting the reads matching to defined gene locations reveals their transcription 
levels  (Nagalakshmi et al. 2010). 
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1.6. Aim of the study 
The limited knowledge of EcPV2 and its association to develop SCC, urge to intensify 
studies of this infectious agent. In particular, the changes in gene expression of 
affected tissue might give new perspectives into the pathological mechanism of the 
associated disease. EcPV2 transcription during infection, as well as, differences 
between host gene expression in healthy horses and horses with EcPV2 positive 
penile SCCs can be determined by RNA-Seq. Information about EcPV2 on the 
transcriptional level might help to further characterize this virus, while the 
categorization of affected biological processes and pathways in the host will open a 
new perspective of the molecular events leading to SCC. Furthermore, potential 
marker genes for the future development of EcPV2 positve SCCs in the affected 
penis of horses will be defined. The underlying hypothesis is that the gene 
expression profile of EcPV2 infected tissue is altered as compared to healthy skin 
cells. The overall gene expression pattern in EcPV2 affected SCC will give clues 
about the mechanisms driving the disease. This study will provide a basis to study 
EcPV2 associated cell changes in more detail and might be useful for the future 
development of diagnostic and prognostic tools in EcPV2 associated SCCs. 
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2. Material and methods 
2.1. Sample material 
Penile skin biopsy samples were collected from five horses with penile squamous cell 
carcinoma, as well as from three horses, which were apparently free of any skin 
lesions. Sampled affected horses were presented for diagnosis and treatment of SCC 
in different horse-clinics in Switzerland or Germany. The samples were either taken 
from diagnostic biopsies or during surgery after excision of the tumour. The clinical 
diagnosis for squamous cell carcinoma was confirmed by histopathological 
examination and the presence of EcPV2 DNA was evaluated by PCR assay. The 
biopsy samples from unaffected horses were collected from recently euthanized or 
slaughtered horses from a Swiss butcher or from horse-clinics in Switzerland or 
Germany. All collected tissue material was immediately immersed in RNA-later 
(SIGMA-ALDRICH, Buchs, CH) and incubated for 24 hours at 4°C. Then RNA-later 
was removed and samples were stored at -70°C until further processing.   
2.2. DNA Extraction and PCR 
DNA was extracted from an approximately two millimetre sized piece of the biopsy 
using QIAamp DNA Minikit (QIAGEN, Germantown, MD) according to the 
manufacture`s protocol. Successful genomic DNA extraction was confirmed by a 
PCR assay designed to amplify equine GAPDH DNA with the primer combination 
ecGAPDH forward primer (5’-GAG CTG AAT GGG AAG CTC AC-3’) and reverse 
primer (5’-CTG AGG GCC TTT CTC CTT CT-3’) (Lange et al. 2013a). For detection 
of EcPV2-DNA, a PCR assay was performed using an EcPV2 specific primer set. 
This assay amplified a 395 base pair fragment of the E6 gene (position 41-435) from 
the genomic sequence of EcPV2 (Gen Bank accession number EU503122), using 
EcPV2-E6 forward primer (E6-41f: 5′-GCTCTCTTCTGGTTACTTTGG-3′) and reverse 
primer (E6-435r: 5′-CTTGCAGTGTACACGTTTCTG-3′) (Scase et al. 2010). PCR 
was performed with a reaction mix containing 8 µl water, 2 µl of each forward and 
reverse primer (10µM each), 1µl extracted DNA as template and 12 µl REDTaq 
ReadyMIX (SIGMA-ALDRICH, Buchs, CH) in a total volume of 25 µl. The cycling 
program for both PCR assays started with a denaturation step of 3 min at 94°C, 
followed by 40 cycles of 30 sec at 94°C, 30 sec at 55°C and 30 sec at 72°C. PCR 
products were separated by electrophoresis through a 1% agarose gel and visualized 
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by ethidium bromide staining. The PCR amplimers were excised from the agarose 
gel and purified using Zymoclean Gel DNA Recovery Kit (ZYMO RESEARCH, Irvine, 
CA) according to the manufacture´s protocol. Nucleotide sequences were determined 
(Microsynth, Balgach, CH) using an ABI 377 sequencer (Applied 
Biosystems/Invitrogen, Basel, CH) and compared to the published reference 
sequences of EcPV2 with the NCBI Basic Local Alignment Search Tool (“BLAST”) 
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) (Altschul et al. 1990). 
2.3. RNA Extraction  
An approximately 2 mm sized piece of the biopsy was cut into small pieces and 
placed in a ZR BashingBead Lysis Tube (ZYMO RESEARCH, Irvine, CA) containing 
500 µl TRIzol Reagent (life technologies, Zug, CH). The sample was homogenized 
by vortexing for at least ten minutes. Afterwards the RNA was extracted using Direct-
zol RNA MiniPrep (ZYMO RESEARCH, Irvine, CA) according to the manufacture´s 
protocol including an in-column DNase I digestion. The quantity and quality of the 
extracted RNA was assessed by the use of a Bioanalyzer 2100 (Agilent, Waldbronn, 
Germany). Samples with a RNA Integrity Number (RIN) of at least 7.2 were included 
in RNA-Seq analyses. For all extracts 400ng were used for further processing by 
RNA-Seq. 
2.4. Illumina RNA Sequencing  
2.4.1. Library preparation 
The quantity and quality of the isolated RNA was determined with the Qubit® (1.0) 
Fluorometer (Life Technologies, California, USA) and the Bioanalyzer 2100 (Agilent, 
Waldbronn, Germany). The SureSelect SS RNA Library Prep (Agilent, Waldbronn, 
Germany) was used in the succeeding steps. Briefly, total RNA samples (1 µg) were 
ribosome depleted and then reverse-transcribed into double-stranded cDNA with 
Actinomycin added during first-strand synthesis. The cDNA samples was fragmented, 
end-repaired and polyadenylated before ligation of TruSeq adapters. The adapters 
contain the index for multiplexing. Fragments containing TruSeq adapters on both 
ends were selectively enriched with PCR. The quality and quantity of the enriched 
libraries were validated using Qubit® (1.0) Fluorometer and the Bioanalyzer 2100 
(Agilent, Waldbronn, Germany). The product is a smear with an average fragment 
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size of approximately 360 base pairs. The libraries were normalized to 10 nM in Tris-
Cl 10 mM, pH 8.5 with 0.1% Tween 20.  
2.4.2. Cluster Generation and Sequencing  
The TruSeq SR Cluster Kit v3-cBot-HS (Illumina, Inc, California, USA) was used for 
cluster generation using 8 pM of pooled normalized libraries on the cBOT. 
Sequencing was performed on the Illumina HiSeq 2000 in single read mode with 
read length of 100 base pairs using the TruSeq SBS Kit v3-HS (Illumina, Inc, 
California, USA)  
2.5. Sequencing data analysis 
After 101 cycles of single-end sequencing, the processing of fluorescent images into 
sequences, base-calling and quality value calculations were performed using the 
Illumina data processing pipeline (version 1.8.2). 
The raw reads were first cleaned by removing adapter sequences, trimming low 
quality ends, and filtering reads with low quality (phred quality <20). Sequence 
alignment of the resulting high-quality reads to the Equine (build: EquCab2) and viral 
genome (EcPV2_GB: EU503122.1) and quantification of gene level expression was 
carried out using “RSEM” (Version 1.2.5) (Li, Dewey 2011). To detect differentially 
expressed genes we applied count based negative binomial model implemented in 
the software package “edgeR” (R version: 3.0.2, edgeR version: 3.4.2) (Robinson et 
al. 2010), in which the normalization factor was calculated by trimmed mean of M 
values (TMM) method (Robinson, Oshlack 2010). The gene-wise dispersions were 
estimated by conditional maximum likelihood and an empirical Bayes procedure was 
used to shrink the dispersions towards a consensus value. The differential 
expression was assessed using an exact test adapted for over-dispersed data. 
Genes showing altered expression with adjusted (Benjamini and Hochberg method) 
p-value < 0.05 were considered differentially expressed. 
2.6. Analysis viral transcriptome 
To characterize the viruses and their transcription within the EcPV2 positive horses, 
in particular, the quantity of the reads, the sequence variations and the splicing of the 
viral mRNA were analysed and represented by Integrative Genomics Viewer “IGV” 
(http://www.broadinstitute.org/igv/) (Robinson et al. 2011; Thorvaldsdóttir et al. 2013). 
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2.7. Analysis horse transcriptome 
The differently expressed genes in EcPV2 positive horses with SCC compared to 
healthy horses with p-values below 0.01 and fold changes above 2 (ؙ ȁ݈݋݃ʹݎܽݐ݅݋ȁ > 
1) were represented in an histogram and used in an unsupervised cluster analysis by 
“R” (http://www.R-project.org/) (R Core Team; R Development Core Team 2013). 
Fold changes (fc) were defined as fc =ʹȁ௟௢௚మ௥௔௧௜௢ȁ. 
2.7.1. Pathway and Biological Processes analysis 
Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway and Gene Ontology 
(GO) term biological processes (BP) analysis was done by three different programs: 
“GSEA” (http://www.broadinstitute.org/gsea) (Mootha et al. 2003; Subramanian et al. 
2005), “STRING” (http://string-db.org) (Franceschini et al. 2013; Szklarczyk et al. 
2011) and “DAVID” (http://david.abcc.ncifcrf.gov) (Huang et al. 2009b, 2009a). A list of 
genes with a p-value < 0.01 and fc > 2 was used for pathway analysis by “DAVID” and 
“STRING”. At the “GSEA” analysis all genes were included depending on the different 
method the program is using. The pathways and terms detected within all the three 
different programs were decided to be the most essential ones. Selected pathways 
were represented using R Bioconductor package “PATHVIEW” 
(http://www.bioconductor.org/packages/release/bioc/html/pathview.html) (Luo, 
Brouwer 2013).  An Enrichment Map of the “GSEA” GO terms BP analysis was 
constructed using “CYTOSCAPE” (Enrichment Map Plugin) (http://www.cytoscape.org) 
(Saito et al. 2012; Cline et al. 2007).  
2.7.2. Detection of potential Marker genes 
To detect potential marker genes a gene list of the TOP 100 up regulated genes with 
the lowest p-values were compared via “EXPRESSIONBLAST” 
(http://www.expression.cs.cmu.edu) (Zinman et al. 2013) against processed data sets 
published on Gene Expression Omnibus (GEO) on the National Center for 
Biotechnology Information (NCBI) (https://www.ncbi.nlm.nih.gov/geo/). Once, 
analysis was done versus the entire database and once versus datasets with 
keyword “carcinoma” to look especially for carcinoma studies.  
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3. Results 
3.1. Horses 
Tissue samples from eight horses were included for RNA-Seq analysis. One group 
consisted of three healthy EcPV2-negative horses and the other group of five horses 
with EcPV2-positive SCCs. More details about these horses are listed in Table 1. The 
mean and median ages of the two groups (mean SCC 18.2 and mean healthy 20 
years) as well as this of eight horses in total (mean 18.8 years) are similar. All horses 
were geldings. Efforts were made to match the breeds and origins represented in 
both healthy and affected group (see Table 1). Every penile lesion was a proliferative 
SCCs and the clinical diagnosis was confirmed by histopathological examination.  
3.2. DNA extraction and PCR 
To check for the presence of viral DNA, from every tissue sample, total DNA was 
extracted and checked for GAPDH-DNA and EcPV2-DNA by PCR. GAPDH-DNA 
could be amplified in all samples, so the successful DNA extraction was confirmed. 
As expected, EcPV2-DNA was detected by using an EcPV2_E6 specific primer pair 
in every sample from penile SCC, but not in the samples from healthy horses. (Table 
1) The sequences of the PCR amplimers were determined. The sequencing results 
showed a similarity of minimum 98% compared to the published EcPV2 sequences 
by “BLAST” analysis (Status 2014) (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi.) 
(Altschul et al. 1990). 
Table 1: Horse samples used in this study  
 
Sample Age Origin Bread Clinics PCR 
1 19 Switzerland Arab/Welsh Pony healthy negative 
2 21 Germany Quarter Mix healthy negative 
3 20 Switzerland Warmblood healthy negative 
4 16 Germany Haflinger SCC EcPV2 
5 14 Germany New Forest Pony SCC EcPV2 
6 21 Switzerland Warmblood SCC EcPV2 
7 18 Germany Haflinger SCC EcPV2 
8 22 Germany Welsh Pony SCC EcPV2 
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3.3. RNA-Seq  
3.3.1. Viral transcriptome 
RNA-Seq analysis was employed to characterize the viruses and their transcription 
within the EcPV2 positive horses. In particular, the sequence variations and the 
splicing of the viral mRNA were analysed. 
3.3.1.1. Viral reads 
To check for the expression of the individual genes, the RNA-Seq reads were 
mapped to the viral genome (EcPV2_GB: EU503122.1.) Hits were detected for all 
samples of EcPV2 positive horses with SCC, but not for samples of healthy horses. 
The read counts of the five positive samples mapped to the EcPV2 genome are 
shown in Figure 1. The gene expression profile of EcPV2 was similar in all samples. 
In ORFs of the late genes only a few reads were noticed, while up to some 
thousands reads in ORFs of the early genes - in particular E6, E7, E4 and E2 - were 
detected. 
 
 
Figure 1: Comparison of the quantity of reads which mapped to the EcPV2 genome.  
The RNA-Seq read counts of the five EcPV2 positive samples mapped to the EcPV2 
genome below the schematic view of the EcPV2 genome. (scale of reads #4: 0-2719; 
#5: 0-1414; #6: 0-993; #7: 0-370, #8: 0-733). In ORFs of L genes only a few reads 
were noticed, while up to some thousands reads in ORFs of E genes were detected. 
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3.3.1.2. Splice junctions EcPV2 
Upon the analysis of the viral reads we recognized that some reads could be mapped 
onto exon junctions. Based on these reads, the corresponding splice junctions could 
be evaluated. The six most frequent EcPV2 splice junctions found in the reads from 
the five positive horses and their associated read counts are shown in Figure 2. Most 
common were junctions between the E1^E2, E1^E2/E4 and E2/E4^E2/E4 region. 
Most prevalent were donors at 964 and 1368 and acceptors at 3370 and 2721. There 
were no intron-spanning reads detected in the late region due to the low sequence 
coverage in this region.  
 
Figure 2: Splice-junctions within the EcPV2 reads.  
The six most frequent EcPV2 splice junctions found in the reads from the five positive 
horses are shown below the schematic view of the EcPV2 genome. The numbering 
of the exon-junctions corresponds to the nucleotide numbering of EcPV2_ZH strain 
(HM461973). The table presents the not standardized read counts over introns in the 
particular samples.  
 
3.3.1.3. Sequence variations in the different EcPV2 genomes 
To characterize the EcPV2 variants in our samples, the sequences revealed from the 
RNA-Seq experiment were compared to the published EcPV2 variants. Thirty-seven 
positions different to the EcPV2_GB variant (EU503122.1) were detected in the five 
samples. These variations were also compared to the EcPV2_ZH (HM461973) 
variant. The resulting sequence variations are shown in Figure 2. There were no 
variations detected in the late region because of the low sequencing coverage 
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(Figure 1). The result of this analysis proposed that sample #4 was closer related to 
EcPV2_GB and the other four samples might have formed yet not recognized EcPV2 
variants. In Detail there were four sequence variations in the E6 ORF, three in the E7 
ORF, 18 in the E1 ORF, twelve in the E2 ORF and none in the E4 ORF. Thereof 23 
were silent, while 14 were non-synonymous point mutations. 
 
Figure 3: Sequence variations  
The EcPV2 sequences detected in the five horses compared to the two published 
sequences are listed below the schematic view of the EcPV2 genome. Cytosin is 
shown in blue, Guanin in black, Thymin in green and Adenin in red. There were 37 
sequence variations, thereof 23 were silent, while 14 were non synonymous point 
mutations. The positions of the sequence variations are written below and the 
nonsynonymous are marked with a star. Two of the non-synonymous point mutations 
were detected in the E6 at position 264 (Ile (ATC) --> Thr (ACC)) and 387 (Arg 
(AGG) --> Thr (ACG)), one in the E7 at position 663 (Thr (ACC) --> Ala (GCC)), two 
in the E1 at position 1592 (Ala (GCG) --> Val (GTG) and 2262 (His (CAC) --> Gln 
(CAG) and nine in the E2 at position 3002 (Ile (ATC) --> Leu (CTC)), 3172 (Gln 
(CAG) --> His (CAC)), 3176 (Val (GTC) --> Ile (ATC)), 3260 (Thr (ACA) --> Ala 
(GCA)), 3734 (Ser (TCT) --> Pro (CCT) 3755 (Asn (ACC) --> Asp (GAC)), 3849 (Lys 
(AAA) --> Arg (AGA)), 3858 (Cys (TGT) --> Ser (TCT)) and 3857 and 3858 both 
together (Cys (TGT) --> Ala (GCT)) 
.  
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3.3.2. Horse transcriptome 
Our next aim was to evaluate differences in the host genes expression in EcPV2 
infected SCC samples compared to healthy tissue samples. Differently expressed 
(DE) genes were characterized and used for further analysis to detect affected 
pathways, GO terms for biological processes and potential marker genes. 
3.3.2.1. Gene counts positive over negative 
The goal was to detect DE host genes in EcPV2 positive SCCs compared to negative 
healthy tissue samples. Therefore, the RNA-Seq reads were mapped to the horse 
genome and a two group comparison analysis of positive over negative samples was 
done. The mapping resulted in 13717 transcripts with counts above the linear 
threshold of 10. These counted reads were used for the analysis of DE genes. The 
gene transcript counts sorted by significance and fc (fc =ʹȁ௟௢௚మ௥௔௧௜௢ȁ) are shown in 
Table 3. In the left part of the table, the number of DE genes according to the 
indicated p-value threshold and the corresponding false discovery rate (FDR) are 
listed. In the right part of the table, the numbers of DE genes depending to 
decreasing p-value thresholds and increasing fc thresholds are shown. As expected 
the number of DE genes decreased with the decreasing p-values, but there were still 
numerous genes with low p-value and high fc. 
Table 3: Sorted significance and fold change of positive over negative gene counts. 
 
The 1957 genes with p-values below 0.01 were used for most of the further analysis. 
All this genes had fold changes above 2 (ؙlog2 ratios >I1I) (Table 3). Their 
distribution depending on log2 ratios is shown in Figure 4. Numerous significant DE 
expressed genes (p<0.01) were quite high up or down regulated. 
#significants FDR fc > 1 fc > 1.5 fc > 2 fc > 3 fc > 4 fc > 8 fc > 10
p < 0.1 4755 0.2882 p < 0.1 4755 4755 3824 2244 1526 635 503
p < 0.05 3610 0.19 p < 0.05 3610 3610 3320 2065 1449 628 500
p < 0.01 1957 0.06994 p < 0.01 1957 1957 1957 1566 1162 580 466
p < 0.001 937 0.01458 p < 0.001 937 937 937 907 771 432 353
p < 1e-04 470 0.002849 p < 1e-04 470 470 470 469 448 296 247
p < 1e-05 257 0.0005194 p < 1e-05 257 257 257 257 254 190 165
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Figure 4: Histogram of log2 ratios p < 0.01 
The histogram shows the distribution of the numbers of genes depending on their 
log2 ratios for the 1957 DE genes with p-values below 0.01. Log2 ratios below zero 
show the downregulated genes while above zero the upregulated genes are shown. 
 
3.3.2.2. Clustering of significant genes 
To compare the gene expression profile within the different samples a cluster 
analysis was done. The 1957 differently expressed genes with p-values below 0.01 
and fc above 2 were used in an unsupervised cluster analysis. The cluster plot is 
shown in Figure 5. The clustering of the up and down regulated genes revealed 
specific patterns for negative and positive samples, respectively. However the 
expression pattern of sample #4 (Positive 1) differed from the patterns of the other 
positive samples. 
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Figure 5: Clustered heatmap of 1957 significant genes  
1957 genes with a significance threshold of p<0.01 and fc >2 were used for 
clustering of significant features. Upregulated genes are depicted in red, while 
downregulated in blue. The three EcPV2 negative samples (#1-3) are on the left side 
and the five positive samples (#4-8) on the right side. 
 
3.3.2.3. KEGG Pathway analysis 
For the detection of affected pathways, which might be involved in the development 
of EcPV2 associated SCC, DE host genes were used for KEGG pathway analysis by 
“GSEA”, “STRING” AND “DAVID”. A list of genes with a p-value <0.01 (1957) were used 
for pathway analysis by “DAVID” and “STRING”, while for “GSEA” analysis all genes 
(13717) with corresponding fc-values were included. The significance of the most 
affected pathways detected by all the three programs is shown in Figure 6. We 
identified the cell cycle including DNA replication as significantly upregulated. Also 
extracellular processes including ECM receptor interaction and focal adhesion were 
recognized to be affected. This suggests that the disease might be driven by 
intracellular factors, which upregulate the mitosis rate and extracellular factors which 
affect interactions between the cells.  
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Figure 6: Significantly affected KEGG pathways by “GSEA”, “STRING” AND “DAVID” 
KEGG pathway analysis was done by “GSEA” (http://www.broadinstitute.org/gsea), 
“STRING” (http://string-db.org) and “DAVID” (http://david.abcc.ncifcrf.gov). For “GSEA” 
analysis all 13717 DE genes were included, while a list of 1957 DE genes with p-
value <0.01 were used for pathway analysis by “DAVID” and “STRING”, according to 
the different methods the programs are using. The four significantly affected 
pathways detected by all the three programs are plotted against the –݈݋݃ଵ଴ (p-values) 
obtained from the different programs. (p-values of “GSEA” analysis below 0,001 are 
shown as 3) 
 
To further characterize the affected genes within the pathways the cell cycle and the 
focal adhesion pathway, the ratios were projected onto the KEGG pathway maps and 
shown in Figure 7. Up or down regulated genes and the intensity of regulation are 
distinguished by the colours given to the genes. In the cell cycle pathway the majority 
of genes were upregulated while there were up as well as down regulated genes in 
the foal adhesion pathway. 
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Figure 7: Affected genes KEGG Pathway Cell Cycle and Focal adhesion 
Schematic graph of KEGG Pathway “cell cycle” and “focal adhesion”. Up regulated 
genes are shown in red and down regulated in green. 
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3.3.2.4. GO term BP analysis 
For the detection of affected biological processes a GO term BP analysis was also 
done by “GSEA”, “STRING” AND “DAVID” with the identical lists of genes as used for the 
KEGG pathway analysis. Figure 8 shows the significance of the seven most enriched 
GO terms detected by all the three programs. This result confirmed the observation 
of the pathway analyses, the cell cycle seems to be significantly regulated, especially 
the Mitosis.  
 
Figure 8: GO terms biological processes analysis 
The –݈݋݃ଵ଴ (p-values) of the seven most significantly enriched GO terms calculated 
by three different programs are plotted. (A “GSEA”  –݈݋݃ଵ଴ (p-values)  at 3 stands for 
p-value < 0.001) 
 
To visualize the affected biological processes, an enrichment map of the GO term BP 
identified by “GSEA” analysis of differentially expressed host genes was constructed 
using “CYTOSCAPE”. As seen in Figure 8 the cell cycle including DNA metabolic 
process is intensely affected. This confirmed the results of the KEGG pathway 
analysis. In addition, RNA processing and response to stress were detected as 
significantly regulated as well. 
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Figure 9: Enrichment Map of the “GSEA” GO terms biological processes analysis 
An Enrichment Map of the “GSEA” GO terms BP analysis was constructed using 
“CYTOSCAPE” (http://www.cytoscape.org/). Nodes represent individual GO terms and 
their sizes correspond to the number of assigned genes. Edges represent common 
genes in the connected nodes and the thickness the numbers of common genes. Cell 
cycle, RNA processing, response to stress and DNA metabolic process are the most 
affected biological processes. 
 
3.3.2.5. Potential marker genes 
Molecular diagnostics for SCC based on elevated gene expression demands the 
identification of marker genes. Therefore, one aim of this study was to define such 
potential marker genes. The hundred most up regulated genes of our study were 
compared by “EXPRESSION BLAST” to gene expression studies published on GEO. The 
analysis was performed twice, either with “carcinoma” as keyword preselected 
datasets or with non-preselected datasets. The results are shown in Figure 10.  
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Figure 10: Heatmap Top 100 upregulated genes compared to other studies 
To detect potential marker genes a gene list of the TOP 100 up regulated genes with 
the lowest p-values were compared via “EXPRESSIONBLAST” (status 07/2014) to other 
gene expression studies. For the heatmap on the left side studies were chosen 
without pre selection and on the right side “carcinoma” was used as a keyword to 
look especially for carcinoma studies. On the left hand side of the plots, the 100 
genes are listed and on the top the 25 most similar studies depending on these 
genes are shown (The corresponding studies are shown in Supplementary Table 3 
and 4). Number 0 is the genelist from this study. Upregulated genes are shown in red 
and downregulated genes in green. In both cases IL8 and MMP1 seem to be intense 
up regulated in many other studies.  
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The analyses with both settings revealed Interleukin 8 (IL8) and Matrix 
Metalloproteinase 1 (MMP1) as up regulated genes in ours as well in many other 
studies. The list of the 100 most upregulated genes sorted by p-values is shown in 
Supplementary Table 2. Both genes revealed high log2 ratios (IL8: 13.85 and MMP1: 
9.43) which resulted in a five or three digit fold fc, respectively (IL8: 14766 and 
MMP1: 690). MMP1 is an interstitial collagenase, which is involved in the breakdown 
of extracellular matrix. IL8 is a chemokine, which induces chemotaxis and is also a 
factor for angiogenesis. Previous studies have reported these genes to be 
upregulated in PV associated cancers (Walker et al. 2011; Hsiao et al. 2013; 
Rajkumar et al. 2011; Mosseri et al. 2014; Yuan et al. 2010; Yuan et al. 2008; Regezi 
et al. 2002; Akgül et al. 2005; Ryzhakova, Solov'eva 2013) and therefore MMP1 and 
IL8 might be useful as biomarkers for the development of SCC in EcPV-2 infected 
tissue. 
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4. Discussion 
The knowledge about EcPV2 and its possible association to develop SCC is still 
limited. Therefore, EcPV2 gene expression and the changes in host gene expression 
of affected tissue were characterized on a transcriptional level for the first time by 
RNA-Seq. By analysis of the viral transcriptome we could quantify the transcription 
levels and the splicing events of viral mRNAs. By analysis of the host’s 
transcriptome, we could confirm our hypothesis that the gene expression profile of 
EcPV2 infected tissue is altered as compared to healthy skin. Our evaluation of these 
differences resulted in 1957 DE host genes. These DE host genes were further 
characterized and revealed biological processes as cell cycle, focal adhesion and 
RNA processing to be the most affected ones. Additionally IL8 and MMP1 were 
defined as potential marker genes that could be used for assessing future 
development of SCCs on the affected penis of horses. 
4.1. Viral transcriptome 
4.1.1. Viral reads 
In the first part of this study, the whole transcriptome of EcPV2 was assessed. The 
analysis of the reads mapped to the viral genome revealed comparable gene 
expression and splicing in all EcPV2-PCR positive samples, while no reads were 
detected in the EcPV2-PCR negative samples. For all positive samples, the gene 
expression profile of EcPV-2 showed high expression of the oncogenes E6 and E7 
and other early genes in particular E4 and E2. While low expression of E1 and almost 
no expression of the late genes L1 and L2 were detected (Figure 1). Similar viral 
gene expression profiles are reported in high risk HPV cancers. The oncogenes E6 
and E7 get deregulated during an HPV16 infection, sometimes due to the integration 
of the viral DNA into the host genome, which might lead to the cancer progression. 
The viral life cycle cannot be completed in such a situation and therefore there is no 
expression of the late capsid proteins (Doorbar 2005; Zur Hausen 2002). RNA-Seq 
analysis of HPV16 positive cervical SCCs and HPV58 positive cervical intraepithelial 
neoplasias (CIN) 2/3 showed similar expression results, except for the E5 gene which 
is not present in EcPV2 (Chen et al. 2014; Yang et al. 2013). The comparison to 
human skin cancer failed as there were no viral reads detected in RNA-Seq analysis 
of papillomavirus positive skin cancers, suggesting that the virus is not active in 
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human cutaneous SCCs (Arron et al. 2011). No complete expression study covering 
all EcPV2 genes in positive SCCs is published yet. Indeed, Van den Top et al. 
determined the expression of the viral genes E2, E6 and L1 in non-invasive and 
invasive lesions. However, no differences in viral mRNA expression between the 
different lesions could be detected. They explained their findings by a possible “hit 
and run” action of EcPV2, suggesting that EcPV2 might lead to a penile intraepithelial 
neoplasia or a papilloma in the horse, while the followed progression to SCC is 
triggered by other mechanisms  (Van den Top, J. G. B. et al. 2014). Therefore a 
longitudinal study of the gene expression in the equine penis papilloma might be very 
helpful. However, since the detailed expression levels were not presented in the 
publication, no further conclusion can be drawn. Likewise, Sykora et al. checked for 
E6 and E1 mRNA expression in 8 SCC samples. They could detect E6 mRNA in all 
the samples, while E1 was only detected in three of the samples. They interpreted 
their results by probable splicing events and reduced primer binding affinity in the 
PCR assay (Sykora et al. 2012). The low E1 expression compared to the higher E6 
expression is in agreement with our RNA-Seq results. In conclusion, we describe 
here the first viral gene expression results covering the entire EcPV2 genome. Due to 
the small sample size of our study, the results should be confirmed in a broader 
range of samples. 
4.1.2. Splice junctions of EcPV2 
Gene expression regulation of PV takes place on the transcriptional level as well as 
on the level of pre-mRNA processing. Much is known about the role of alternative 
splicing for the regulation of HPV16 RNA processing during the early and late stages 
of infection, while there exists not much information about EcPV2 pre-mRNA 
processing yet (Johansson, Schwartz 2013). Transcript maps for BPV1 and several 
HPVs are available on PAVE (http://pave.niaid.nih.gov/) (van Doorslaer et al. 2013), 
but not for EcPVs. Therefore we screened the RNA-Seq data for detection of splice 
events in EcPV2 infected tissue. 21 EcPV2 splice junctions on intron-spanning reads 
could be detected. Thereof the six most frequent splice junctions (with more than 50 
reads in total over all samples) are shown in Figure 2. The most common junctions 
are between E1^E2/E4, E1^E2 and E2/E4^E2/E4, while most prevalent are donors at 
nucleotide position 964 and 1368 and acceptors at 3370 and 2721. Two of the 
products are predicted spliced genes (in detail E1^E4 (943..964, 3370..3767) and 
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E8^E2 (1331..1368, 3370..4018)) of the EcPV2 genome by PAVE 
(http://pave.niaid.nih.gov/) (van Doorslaer et al. 2013). All acceptors and donors, 
except of the donor at nucleotide position 1368, were splice sites in silico predicted 
by NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/) (Brunak et al. 1991; 
Hebsgaard et al. 1996). The positions of the most prevalent donors at nucleotide 
position 964 and 1368 and acceptors at 3370 and 2721 relative to the ORFs are 
similar to published splice sites of diverse HPVs and BPV1 genomes 
(http://pave.niaid.nih.gov/)  (Johansson, Schwartz 2013; van Doorslaer et al. 2013) 
and the coding potentials of the mature mRNAs might be comparable.  
The most frequently detected splice junction ( E1^E4 964-3370) has also been 
described for many HPVs and BPV1, thus, representing splice donor and acceptor 
sites that are conserved across different PV types (http://pave.niaid.nih.gov/) (van 
Doorslaer et al. 2013). It is known that E4 gene products are expressed from these 
E1̰E4 spliced mRNA (Doorbar 2013) and therefore this splice junction is in the case 
of EcPV2 also the most likely one used to express the E4 gene. The E4 protein has 
been suggested to serve as a biomarker of active virus infection, and, in the case of 
high-risk HPV types, also disease severity. It may account for as much as 30% of 
total lesional protein content. Therefore, it can easily be visualised in biopsy material 
by immunostaining. Functionally, the E4 protein may facilitate efficient virus release 
and transmission, while, during early phases, also contributing to genome 
amplification-efficiency (Doorbar 2013). In the future, detection of EcPV2 E4 protein 
in equine lesions should be established to further assess the virus's contribution 
equine carcinomas.  
The second and fourth most frequent splice junctions (E1^E2 964-2720 and E1^E2 
1368-2720) have the same splice acceptor (2720) in common which is also a 
conserved splice acceptor in other PVs (http://pave.niaid.nih.gov/) (van Doorslaer et 
al. 2013). It is known that splicing to this acceptor generates mRNAs for expression 
of full length E2 protein (Johansson, Schwartz 2013), suggesting that this might be 
the case for EcPV2 as well. Comparable splice junctions like the first (964-2721) are 
present in almost all HPVs, while the second one (1368-2721) is only detected in 
BPV1 and a few HPVs (HPV5, HPV11, HPV47) (http://pave.niaid.nih.gov/) (van 
Doorslaer et al. 2013). The E2 proteins function as the main transcriptional regulators 
of PVs, by recruiting cellular factors to the viral genomes, which activate or repress 
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transcriptional processes. Besides the full length E2 transcript, all PVS have the 
potential to encode shorter E2 forms by spliced messages that link sequences from 
an alternative reading frame in the E1 region of the genome (designated E8) to the 
C-terminus of E2 (McBride 2013). This splice junction (1368-3370) named E8^E2 is 
also present in the EcPV2 transcripts. This shorter form of E2 functions as a 
repressor of viral transcription and replication (McBride 2013). 
Not much information is available for the two short splice junctions E2/E4^E2/E4 
(3197-3370 and 3528-3653). A similar junction like our first E2/E4^E2/E4 (3197-
3369) was detected in HPV18. There, the splice donor site is located in the 5′ part of 
E2, while the splice acceptor site is the one used for E1^E4, like in our detected 
EcPV2 junction. The level of E2^E4 spliced transcripts seems to increase during 
keratinocyte differentiation. These E2^E4 fusion proteins are cytoplasmic and can 
probably induce cell death. Though the functions of these proteins are not completely 
understood, it is believed, that they could functionally mimic the E2/E1^E4 interaction 
and could also exhibit new functions that might be important for the viral life cycle and 
pathophysiology (Tan et al. 2012). A similar junction like the other short E2/E4^E2/E4 
splice junction (3528-3653) was only detected once in HPV5. There, for the first time 
an internal splice site in the E4 ORF was recognized in putative L2 messages. By 
PCR with E1/L2 and NCR/L2 specific primer pairs, a peculiar E4 internal splice site 
was detected. While the transcript starting from the NCR seem to encode for a 
putative L2 message, the transcript starting from E1 might encode for L2 and 
truncated E1^E4 protein with unknown function (Haller et al. 1995).  
It has to be kept in mind, that by RNA-Seq only small reads of mRNA are detected. 
Consequently, we have just information about the splice junctions and no information 
about the whole generated mRNA transcript. Furthermore, we do not know the 
combination of more than one splice event during processing of pre-mRNA to a 
certain mRNA. Therefore by comparing to the literature, just suggestions about the 
coding potential of these mRNAs could be done. To figure out, which whole mRNA 
transcripts are generated by EcPV2 and what the functions of these transcripts and 
their translation products are, further experiments are needed. However, in this study 
for the first time splice junctions of EcPV2 were detected. The four most frequent are 
in common with other PVs and have predicted functions, which might be conferrable 
to EcPV2. Two further small splice junctions, which seem to be not so much 
32 
 
conserved in other PVS, were recognized in the E2 and E4 region. To understand 
the functions of this alternative splicing further studies are warranted. Finally, one 
may consider that also introns may be of biological relevance, for example in the form 
of micro RNA as fine-tuning regulators of gene expression. However, presently no 
bioinformatical evidence in this context could be generated.  
4.2. Horse transcriptome 
4.2.1. Biological processes 
In the second part of this study, the transcriptomes of EcPV2 affected and non-
affected horse tissues were compared and identified DE genes were analysed to 
reveal the involved pathomechanisms driving this disease. Enrichment analysis for 
biological processes was performed by several programs. The most affected 
processes are on the one hand the cell cycle and RNA processing and on the other 
hand ECM receptor interaction and focal adhesion. 
The most significantly influenced biological process is the cell cycle, in particular the 
mitosis (Figure 6, 7, 8, 9). As a higher mitosis rate is expected in cancerous tissue, 
these results are explainable by the cancerogenesis, as well as in some aspects by 
the virus or both. It is well known, that the cell cycle is upregulated during PV cancer 
development. The cell cycle genes have been described to be one of the main 
drivers of cervical cancer (Mine et al. 2013). Furthermore, by expression analysis 
using microarrays, genes involved in cell cycle and cell proliferation were detected to 
be dysregulated in BPV1 associated equine sarcoid (Yuan et al. 2008). Of note, it 
seems that cell cycle and DNA damage response are much stronger affected by 
high-risk HPV as compared to low-risk HPV (Santegoets, Lindy A M et al. 2012). As 
EcPV2 seems to be an “equine high-risk PV” this might be the reason for upregulated 
cell cycle similar to HPV infections. In particular the interaction of the HPV oncogenes 
E6 and E7 with regulators of the cell cycle are known to be the cause of cervical 
cancer. (Clarke, Chetty 2001). As our study shows a high expression of the EcPV2 
oncogenes E6 and E7 (Figure 1), it might also explain the upregulation of the cell 
cycle. The oncoproteins E6 and E7 induce immortalization of cells partly through their 
inhibitory effects on tumour suppressor proteins pRb and p53. The pRb’s growth-
inhibitory role allows release of E2F transcription factors, from which some 
associated genes are also upregulated in our study, especially E2F1 (Figure 7; 
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Supplementary Table 1). Increased E2F grants limitless proliferative potential by 
allowing expression of products such as cyclins A, E, and B, dihydrofolate reductase, 
and DNA polymerase which provokes various stages of the cell cycle and leads to 
override the G1–S and G2–M cell cycle checkpoints. Upregulation of a gene 
encoding for cyclin A, (in detail CCNA2) was also detected in this study (Figure 7 and 
Supplementary Table 1) and it is known, that cyclin A promotes anchorage-
independent growth, which facilitates tissue invasion and tumour spread (Clarke, 
Chetty 2001). In general the cyclin-dependent protein kinases (CDKs) are known to 
be the key regulators of the eukaryotic cell cycle. The successive activation of 
various CDKs is required for the passage through the cell cycle. They build 
complexes with cyclin, which promote progression towards DNA replication. The 
CDK/cyclin complexes phosphorylate proteins required for the activation of genes 
involved in DNA synthesis, DNA replication and the entry of cells into mitosis (Nigg 
1995). CDK2, CDK3, CDK4 and CDK6 drive cells through interphase and CDK1 is 
needed to proceed the cell through mitosis (Malumbres, Barbacid 2005). Of note, 
CDK1 seems to be the only essential cell cycle CDK. After phosphorylation of the 
retinoblastoma protein pRb and the expression of genes that are regulated by E2F 
transcription factors, CDK1 can bind to all cyclins and hence can execute all the 
events that are required to drive cell division in the absence of interphase CDKs 
(Santamaría et al. 2007). Genes encoding for CDKs and cyclins, in particular CDK1 
and CDK4, as well as for Cyclin A, B and D (in particular CCNA2, CCNB1, CCNB2, 
CCNB3, CCND2), are shown to be up regulated in EcPV2 infected cancer tissue 
samples (Figure 7; Supplementary Table 1). This might be a possible explanation for 
the upregulated cell cycle. However, many other factors like phosphorylation play a 
role in these biological processes and posttranscriptional changes, as 
phosphorylation, were not addressed by this study. The exact mechanisms involved 
in the detected processes have to be studied in more detail in future experiments.  
Several post-transcriptional regulations, in particular RNA processing, were detected 
as significantly dysregulated in the EcPV2 positive horses (Figure 9). This might be 
explainable through the presence of the PV. Since PV genomes are small and 
compact, post-transcriptional regulation is important to complete their life cycle and, 
regulation of RNA processing in the nucleus is essential for the regulation of viral 
gene expression (Graham 2010). Such changes are also observed in equine BPV1 
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associated sarcoids, where a number of genes involved in transcription regulation 
and RNA processing and metabolism are deregulated (Yuan et al. 2008).  
Besides these intracellular factors described above, extracellular factors were 
detected by the pathway analysis, too. Two significantly affected pathways, ECM 
receptor interaction and focal adhesion, were identified (Figure 6). Deregulation of 
these pathways is beneficial to support the survival, growth, and invasion of cancer 
cells and is an essential player at various stages of the carcinogenic process (Lu et 
al. 2012). Besides the regulation by the CDKs, the balance between cell cycle arrest 
and cell proliferation is controlled by the extracellular matrix and contact inhibition 
(Gérard, Goldbeter 2014). Genes involved in cell adhesion, motility, and integrity are 
also affected in BPV1 positive equine sarcoids (Yuan et al. 2008). The influence of 
PV infection on the focal adhesion was already shown by several studies. The E6 
protein was reported to induce a strong modulation of focal adhesion through the 
degradation of TAp63β protein (Ben Khalifa et al. 2011), by the interaction with 
paxicillin and FAK (Tong, Howley 1997; Sarode, Sarode 2014) or by modulation of 
β1-integrin signalling (Holloway, Storey 2014). From these genes only these for the 
integrins, which were described as elevated in non-melanoma skin cancer, were 
affected in our study (Figure 7). The most affected ones are ITGA3, ITGA6, ITGAX, 
ITGB1, ITGB2 and ITGB4 (Supplementary Table 1). Of note, the specific interactions 
between cells and the ECM are mainly mediated by integrins, which function as 
mechanoreceptors and provide a force-transmitting physical link between the ECM 
and the cytoskeleton (http://www.genome.jp/kegg-bin/show_pathway?hsa04512) 
(Kanehisa, Goto 2000; Kanehisa et al. 2014). The integrins seem to have a key role 
in the ECM receptor interaction and focal adhesion pathway. As shown in Figure 7, 
the increased ECM receptor interaction has a direct influence on the focal adhesion 
pathway, as well as the cytokine receptor interaction. Finally, the disturbances of the 
focal adhesion pathway seen in our study result in an up regulation of the cell cycle 
by increased proliferation (in particular via Cyclin D). In conclusion all the detected 
extra- and intracellular factors in the pathway and biological processes analysis are 
interconnected. These changes might be induced by the EcPV2 infection and might 
also be caused by or resulting in the cancer development. 
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4.2.2. Potential marker genes 
Another aim of this study was the definition of potential marker genes for the 
development of SCC in PV affected horses, which could be useful for diagnosis and 
prognosis. Two potential genes were detected: MMP1 and IL8 (Figure 10). Both 
genes were recognized to be increased in many other cancer studies 
(Supplementary Table 3 and 4) and their proteins are known to have an influence on 
the ECM receptor interaction and thus focal adhesion. 
MMP1 is part of the MMP (matrix metalloproteinase) family, which is involved in the 
breakdown of extracellular matrix in normal physiological processes, as well as in 
disease processes. The function of MMP1 is degradation of collagen type I, II and III 
(http://www.ncbi.nlm.nih.gov/gene/4312) (Pruitt et al. 2014). It has been 
demonstrated, that the MMPs play a causal role in tumour cell invasion by initiating 
degradation of basement membrane and extracellular matrix (Westermarck, Kahari 
1999). Some studies show an up regulation of the MMP1 gene in PV associated 
cancers. MMP1 gene expression is essentially increased by HPV E7 oncoprotein in 
most HPV 16 and 18 positive cell lines and was also described to be upregulated in 
cervical cancers (Ryzhakova, Solov'eva 2013; Rajkumar et al. 2011). In HPV8 the E7 
protein has been shown to stimulate the overexpression of MMP1 protein, too. This 
overexpression promotes an invasive phenotype by degradation of the basal 
membrane and ECM, which then allows invasion of human keratinocytes into the 
dermis (Akgül et al. 2005). Of note, MMP1 gene and protein expression is not or only 
moderately expressed in HPV positive dysplastic oral warts while it is highly 
expressed in oral HPV positive SCCs (Regezi et al. 2002). This might allow to define 
this gene as a prognosticator. Interestingly, it was shown that BPV1 also upregulates 
MMP1 gene expression in horses, while the MMP1 protein is essential for the 
transformation of sarcoid fibroblasts (Yuan et al. 2008; Yuan et al. 2010) and it was 
also already suggested that there is a causal correlation between MMP1 protein 
expression and the local aggressiveness of sarcoids regardless of the clinical type 
(Mosseri et al. 2014). These findings indicate that MMP1 might have an important 
impact on the formation of SCCs and might be a potential biomarker for the 
development of EcPV2 associated penile SCCs.  
IL8 also known as CXCL8 (chemokine (C-X-C motif) ligand 8) is a member of the 
CXC chemokine family. IL8 is one of the major mediators of the inflammatory 
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response and functions as a chemoattractant, but it is also a potent angiogenic factor 
(http://www.ncbi.nlm.nih.gov/gene/3576) (Pruitt et al. 2014). Elevated expression of 
IL8 has been characterized in cancer cells, endothelial cells, infiltrating neutrophils, 
and tumour-associated macrophages. Therefore IL8 might function as a significant 
regulatory factor within the tumour microenvironment. Furthermore, inhibiting the 
effects of IL-8 signaling was suggested as a therapeutic option for cancer (Waugh, 
David J J, Wilson 2008). Interestingly, the functions of IL8 and the MMPs seem to be 
connected since IL-8 directly enhances endothelial cell survival, proliferation, MMP 
production and regulated angiogenesis (Li et al. 2003). Particularly the up regulation 
of MMP-2 and MMP-9 expression and activity is induced by IL8 (Shiau et al. 2013). 
Of note, the IL8 gene is known to be upregulated amongst other genes in cervical 
cancers (Rajkumar et al. 2011). The expression of E6 and E7 proteins seems to 
come along with raised IL8 expression during PV infections (Walker et al. 2011; 
Hsiao et al. 2013). As increased IL8 signaling is indeed reported in numerous solid 
tumours during the most advanced stages of disease, (Waugh, David J J, Wilson 
2008) it might also be useful as a potential marker for development of SCC.  
In conclusion we detected two potential candidates, which could serve as marker 
genes for prognosis and diagnosis. However as there are no virus negative SCC 
horses and no healthy EcPV2 horses included in our study, it cannot be distinguished 
if the changes derive from the viral infection or the cancer development or both. The 
identification of the potential marker genes as well as all the other results need to be 
validated in a broader range of samples and confirmed by different methods. 
In this study we gained valuable new information about EcPV2 and its influence on 
the host’s gene expression. In summary we could identify the mainly affected 
biological processes and potential marker genes. Furthermore, we could quantify the 
transcription from the viral genome and the splicing events of some viral mRNAs. 
These results will be the basis to study EcPV2 and its associated cell changes in 
more detail.  
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Supplementary Tables 
Supplementary Table 1: affected genes in KEGG pathways 
hgnc_symbol log2 Ratio p-value fdr hsa03030  hsa04110 hsa04512 hsa04510 
BAD 3,109 0,00001852 0,0008056        X 
BUB1 2,221 0,00057 0,00996    X     
BUB1B 1,955 0,002056 0,02411    X     
CAPN2 2,064 9,703E-06 0,0005194        X 
CAV2 2,178 0,00006066 0,002015        X 
CCNA2 2,467 0,0005901 0,01021    X     
CCNB1 3,192 0,00003809 0,001414    X     
CCNB2 2,103 0,005815 0,04933    X     
CCNB3 3,236 0,0002414 0,005431    X     
CCND2 2,879 0,0001073 0,00308    X    X 
CDC14A -2,549 0,0001073 0,00308    X     
CDC20 2,609 0,0003003 0,006375    X     
CDC25B 1,663 0,006335 0,05213    X     
CDC25C 2,632 0,0005934 0,01023    X     
CDC6 2,651 0,0002071 0,004873    X     
CDK1 3,424 0,00006274 0,002059    X     
CDK4 1,811 0,0007708 0,0122    X     
COL11A1 5,407 0,00001263 0,0006182      X  X 
COL1A1 2,412 0,0006881 0,01129      X  X 
COL3A1 2,064 0,0007525 0,01203      X  X 
COL4A1 2,909 1,445E-08 2,872E-06      X  X 
COL4A2 2,014 0,0001794 0,004409      X  X 
COL5A1 1,676 0,008817 0,06499      X  X 
COL5A2 1,871 0,0002378 0,005366      X  X 
COMP 4,163 0,002266 0,02594      X  X 
CTNNB1 1,419 0,001338 0,01811        X 
DBF4 1,546 0,004163 0,03958    X     
DOCK1 -1,286 0,005054 0,04505        X 
E2F1 1,899 0,007072 0,05603    X     
FEN1 1,974 0,002205 0,02546  X       
FLNC -2,231 0,00789 0,06002        X 
FN1 1,736 0,009121 0,06626      X  X 
GADD45A 3,132 0,00006793 0,002193    X     
HDAC1 1,421 0,001223 0,017    X     
HMMR 2,823 0,0002259 0,005172      X   
IBSP 6,451 0,006076 0,05075      X  X 
ITGA3 3,267 0,00001596 0,0007248      X  X 
ITGA6 1,4 0,008375 0,06246      X  X 
ITGB1 2,577 7,569E-06 0,0004308      X  X 
ITGB4 1,755 0,002538 0,02818      X  X 
JUN 1,754 0,0004201 0,008004        X 
II 
 
LAMB3 1,581 0,009048 0,06604      X  X 
LAMC2 1,83 0,008117 0,06114      X  X 
LIG1 1,327 0,007152 0,05648  X       
MAD2L1 1,31 0,009139 0,06626    X     
MCM2 1,805 0,002316 0,02641  X  X     
MCM3 1,747 0,001537 0,01974  X  X     
MCM4 2,047 0,001029 0,01493  X  X     
MCM5 2,298 0,0005877 0,01018  X  X     
MCM6 2,075 0,0006058 0,01037  X  X     
MCM7 1,946 0,0006018 0,01032  X  X     
MET 1,327 0,004514 0,04162        X 
MYL12A 1,689 0,0002891 0,006187        X 
PAK1 2,599 0,0002107 0,004923        X 
PAK7 -6,942 1,646E-15 1,613E-12        X 
PARVA 2,342 0,001226 0,017        X 
PCNA 1,796 0,001804 0,02206  X  X     
PDGFC 1,503 0,00841 0,06266        X 
PDPK1 -1,459 0,001349 0,01818        X 
PIK3CD -2,307 3,022E-06 0,0002115        X 
PLK1 2,914 0,0001397 0,003726    X     
POLA2 2,118 0,0008051 0,01259  X       
POLE4 2,037 0,0005572 0,00988  X       
PTTG1 -1,286 0,005054 0,04505    X     
RAP1B 2,139 0,002041 0,02399        X 
RFC2 1,619 0,006321 0,05208  X       
RFC3 1,78 0,005165 0,04551  X       
RFC4 2,367 0,0004178 0,00799  X       
RNASEH2B 1,727 0,002608 0,02869  X       
RNASEH2C 2,891 0,003686 0,03619  X       
RPA3 1,892 0,0003866 0,007598  X       
SDC4 1,581 0,001354 0,0182      X   
SFN 1,41 0,002577 0,02848    X     
SHC4 -3,036 0,003904 0,03771        X 
SMAD2 1,304 0,009543 0,06798    X     
SMC1B 7,146 7,343E-07 0,00006995    X     
SPP1 4,185 0,0001543 0,00397      X  X 
SSBP1 1,673 0,001628 0,02059  X       
THBS1 2,066 0,00072 0,01163      X  X 
THBS2 3,791 1,916E-06 0,0001452      X  X 
THBS4 4,354 0,00001266 0,0006182      X  X 
TNC 3,637 1,648E-07 0,00002113      X  X 
TNXB -4,07 0,00006213 0,002051      X  X 
TTK 2,164 0,00104 0,01503    X     
VASP 1,717 0,0009129 0,01385        X 
VAV1 1,871 0,002142 0,02483        X 
VAV2 1,89 0,007422 0,05768        X 
III 
 
Supplementary Table 2: 100 most upregulated genes depending on the p-value 
hgnc_symbol log2 ratio p-value fdr 
 
hgnc_symbol log2 ratio p-value fdr 
PTHLH 6,85 2,69E-11 1,37E-08 
 
CXCL2 5,45 5,83E-07 5,99E-05 
ATP8A2 11,05 1,22E-10 5,40E-08 
 
FRMPD4 5,04 5,83E-07 5,99E-05 
SLPI 7,04 1,86E-10 7,49E-08 
 
IRF7 3,46 6,40E-07 6,45E-05 
S100A6 3,62 2,01E-10 7,87E-08 
 
SLC1A5 2,88 6,64E-07 6,60E-05 
ALDH1A2 5,13 3,33E-10 1,20E-07 
 
PTX3 5,94 6,96E-07 6,82E-05 
SDK2 5,42 3,75E-10 1,32E-07 
 
CSF3R 5,66 7,03E-07 6,84E-05 
PHLDA1 5,29 3,96E-10 1,36E-07 
 
SMC1B 7,15 7,34E-07 7,00E-05 
ISG15 4,51 7,39E-10 2,42E-07 
 
C9orf89 3,52 7,45E-07 7,05E-05 
SLC39A4 6,65 1,18E-09 3,70E-07 
 
STK31 11,10 7,51E-07 7,06E-05 
ID1 3,20 1,19E-09 3,70E-07 
 
CA9 4,61 8,61E-07 7,95E-05 
IL8 13,85 1,36E-09 4,03E-07 
 
PPA1 2,95 8,64E-07 7,95E-05 
MMP13 9,58 1,43E-09 4,09E-07 
 
LGALS9C 3,02 9,32E-07 8,47E-05 
LTBP1 2,90 1,85E-09 5,08E-07 
 
TXNDC17 2,41 9,82E-07 8,75E-05 
TSPAN15 4,85 2,30E-09 6,06E-07 
 
TXN 3,11 9,89E-07 8,75E-05 
IFIT1 3,75 4,21E-09 1,01E-06 
 
MUC20 3,18 9,99E-07 8,79E-05 
C14orf164 4,33 6,10E-09 1,39E-06 
 
SAT1 2,83 1,05E-06 9,08E-05 
FHL2 5,16 7,66E-09 1,72E-06 
 
CD68 3,23 1,08E-06 9,30E-05 
PITX1 6,61 1,15E-08 2,43E-06 
 
GLIPR1 2,40 1,27E-06 1,08E-04 
COL4A1 2,91 1,45E-08 2,87E-06 
 
KDELR3 4,05 1,28E-06 1,08E-04 
S100A11 3,23 1,72E-08 3,28E-06 
 
TNS4 3,65 1,34E-06 1,10E-04 
MMP1 9,43 2,00E-08 3,76E-06 
 
FGD2 3,87 1,38E-06 1,13E-04 
SLC16A3 3,77 2,31E-08 4,28E-06 
 
ARSJ 2,90 1,50E-06 1,20E-04 
TREM1 12,26 3,23E-08 5,68E-06 
 
FCGBP 2,58 1,60E-06 1,27E-04 
SLC9B2 3,57 3,58E-08 6,15E-06 
 
SYCE2 7,01 1,84E-06 1,42E-04 
TMPRSS4 4,41 3,59E-08 6,15E-06 
 
PDLIM7 2,68 1,90E-06 1,44E-04 
S100A2 5,32 4,62E-08 7,64E-06 
 
THBS2 3,79 1,92E-06 1,45E-04 
RBP1 3,79 5,23E-08 8,45E-06 
 
CCL4 3,03 2,12E-06 1,56E-04 
MYBL2 4,34 6,05E-08 9,54E-06 
 
PIWIL1 10,39 2,29E-06 1,68E-04 
MYO5A 2,92 6,15E-08 9,58E-06 
 
CXCL6 7,68 2,32E-06 1,69E-04 
MMP9 7,19 6,34E-08 9,77E-06 
 
ARG2 3,22 2,82E-06 2,02E-04 
CCL2 5,00 6,86E-08 1,04E-05 
 
CYP27B1 7,21 2,85E-06 2,02E-04 
EPOR 5,76 6,99E-08 1,04E-05 
 
GPR110 3,81 2,91E-06 2,05E-04 
IGF2BP2 6,30 7,78E-08 1,15E-05 
 
SERPINB6 2,70 3,13E-06 2,18E-04 
KRT14 3,18 8,92E-08 1,29E-05 
 
PADI3 7,34 3,16E-06 2,19E-04 
ACOT9 3,12 9,19E-08 1,30E-05 
 
DZIP1 2,40 3,27E-06 2,25E-04 
NDRG1 3,66 9,38E-08 1,31E-05 
 
IRG1 6,80 3,51E-06 2,40E-04 
AGR2 8,06 1,13E-07 1,54E-05 
 
UBE2C 3,70 3,77E-06 2,50E-04 
RND1 3,48 1,40E-07 1,85E-05 
 
ALDH3A1 4,70 3,82E-06 2,52E-04 
SATL1 8,16 1,59E-07 2,06E-05 
 
KCNE3 4,33 4,41E-06 2,87E-04 
TNC 3,64 1,65E-07 2,11E-05 
 
IGFBP2 2,33 4,66E-06 2,97E-04 
BACE2 2,98 1,83E-07 2,32E-05 
 
ZFYVE28 8,37 4,67E-06 2,97E-04 
RGL3 5,83 2,60E-07 3,16E-05 
 
ANXA1 3,41 4,70E-06 2,97E-04 
PLAUR 5,46 3,42E-07 4,01E-05 
 
ADAMDEC1 9,67 4,80E-06 3,01E-04 
PMEPA1 3,93 3,47E-07 4,03E-05 
 
MX2 4,33 5,11E-06 3,15E-04 
BNC1 3,47 3,69E-07 4,22E-05 
 
GPX8 2,96 5,22E-06 3,21E-04 
MSANTD3 3,77 3,89E-07 4,41E-05 
 
ZNF114 3,71 5,69E-06 3,48E-04 
CWH43 5,03 4,23E-07 4,68E-05 
 
P4HA3 3,75 6,35E-06 3,77E-04 
SULF1 3,96 4,45E-07 4,85E-05 
 
DSG2 2,96 6,64E-06 3,91E-04 
SERPINE2 3,87 4,58E-07 4,95E-05 
 
MARCKSL1 2,91 6,83E-06 3,99E-04 
S100A10 3,21 4,79E-07 5,09E-05 
 
SPARC 2,50 7,37E-06 4,25E-04 
IV 
 
Supplementary Table 3: “EXPRESSION BLAST” matches no preselection 
Nr GSE PMID Description 
0   This study Top 100 of this study (Supplementary Table2) 
1 12630 PMID:19332734 
Gene expression profiles of poorly differentiated undifferentiated 
and metastatic cancers  
2 33116 
 
Breast cancer and liver tissue biopsies used to develop and 
validate an index for liver contamination in metastatic breast 
cancer  
3 20916 PMID:20957034  
Modeling oncogenic signaling in colon tumors by multidirectional 
analyses of microarray data  
4 27157 PMID:22276141 
Prognostic Significance and Gene Expression Profiles of p53 
Mutations in Microsatellite Stable Stage III Colorectal 
Adenocarcinoma  
5 22563 
 
Identification of TSGs Frequently Methylated in Renal Cell 
carcinoma expression profiles of Renal cell lines following de 
methylation  
6 43029 PMID:23630276  
RNASET2 silenced and control OVCAR3 cell clones injected into 
nude mice  
7 4271 PMID:16530701 
Molecular subclasses of high grade glioma prognosis disease 
progression and neurogenesis  
8 29721 PMID:21747116 
The landscape of promoter DNA hypomethylation in liver cancer 
expression data  
9 25251 PMID:21684623 
Establishment and Comparative Characterization of Novel Non 
Small Cell Lung Cancer Cell Lines and Their Corresponding Tumor 
Tissue  
10 21122 PMID:20601955 
Whole transcript expression data for soft tissue sarcoma tumors 
and control normal fat specimens  
11 22544 PMID:20799942 
Integration of transcript expression copy number and LOH analysis 
of infiltrating ductal carcinoma of the breast expression analysis  
12 27480 PMID:21952923 
Gene expression analysis of Oncostatin M OSM signalling in 
cervical squamous cell carcinomas over expressing the Oncostatin 
M receptor OSMR  
13 9750 PMID:18506748 Identification of gene expression profiles in cervical cancer  
 
V 
 
14 21687 PMID:20639864 
Comparative genomics matches mutations and cells to generate 
faithful ependymoma models  
15 9844 PMID:18254958 Transcriptomic Dissection of Tongue Squamous Cell Carcinoma  
16 41258 PMID:19359472 Expression data from colorectal cancer patients  
17 44408 
 
Transcriptomic survey of lymph node positive vs negative ductal 
breast cancer  
18 10972 PMID:18538736  Colon cancer  
19 5364 PMID:18636107 
A Precisely Regulated Gene Expression Cassette Potently 
Modulates Metastasis and Survival in Multiple Solid Cancers  
20 29570 
 
The mtDNA Amerindian Haplogroup B2 enhances the risk for 
Cervical Cancer of HPV de regulation of mitochondrial genes may 
be involved  
21 6956 PMID:18245496  
Tumor Immunobiological Differences in Prostate Cancer between 
African American and European American Men  
22 17674 PMID:22084725 
Inflammatory gene profiling of Ewing sarcoma family of tumors set 
B  
23 36895 PMID:22683710 
Molecular Genetic Classification of clear cell Renal Cell Carcinoma 
ccRCC based on the Gene Expression Profiling of Tumors and 
Tumorgrafts deficient for BAP1 or PBRM1  
24 27854 PMID:23065711 
Overexpression of NUCKS1 in colorectal cancer correlates with 
recurrence after curative surgery gene expression analysis  
25 17679 PMID:22084725 Inflammatory gene profiling of Ewing sarcoma family of tumors  
 
 
 
 
 
 
 
 
 
 
VI 
 
Supplementary Table 4: “EXPRESSION BLAST” matches preselection “carcinoma” 
Nr GSE PMID Description 
0   This study Top 100 of this study (Supplementary Table 2) 
1 13601 PMID:19138406 
Oral tongue cancer gene expression profiling Identification of 
novel potential prognosticators  
2 20916 PMID:20957034 
Modeling oncogenic signaling in colon tumors by multidirectional 
analyses of microarray data  
3 22563 
 
Identification of TSGs Frequently Methylated in Renal Cell 
carcinoma expression profiles of Renal cell lines following de 
methylation  
4 29721 PMID:21747116  
The landscape of promoter DNA hypomethylation in liver cancer 
expression data  
5 6008 PMID:16452189 Human ovarian tumors and normal ovaries  
6 22544 PMID:20799942 
Integration of transcript expression copy number and LOH 
analysis of infiltrating ductal carcinoma of the breast expression 
analysis  
7 18462 
 
Comparison of gene expression profiles between paired primary 
and metastasis colorectal carcinoma  
8 27155 PMID:16007166  Human thyroid adenomas carcinomas and normals  
9 9844 PMID:18254958 Transcriptomic Dissection of Tongue Squamous Cell Carcinoma  
10 41258 PMID:19359472 Expression data from colorectal cancer patients  
11 21422 PMID:21314937 
Expression profiling of human DCIS and invasive ductal breast 
carcinoma  
12 36895 PMID:22683710 
Molecular Genetic Classification of clear cell Renal Cell 
Carcinoma ccRCC based on the Gene Expression Profiling of 
Tumors and Tumorgrafts deficient for BAP1 or PBRM1  
13 14323 PMID:19098997 
RMA expression data for liver samples from subjects with HCV 
HCV HCC or normal liver  
14 33426 PMID:22280838 
Three Dimensional Tumor Profiling Reveals Minimal mRNA 
Heterogeneity in Esophageal Squamous Cell Carcinoma  
15 39612 PMID:23223137 
Distinct gene expression profiles of viral and non viral associated 
Merkel cell carcinoma revealed by transcriptome analysis  
16 17856 PMID:20380719 
Gene expression in nontumoral liver tissue and recurrence free 
survival in hepatitis C virus positive HCC  
VII 
 
17 16873 PMID:19700746 
Early Dysregulation of Cell Adhesion and Extracellular Matrix 
Pathways in Breast Cancer Progression  
18 23772 
 
Why does HAMLET preferentially kill tumor cells p38 dependent 
death in tumor but up regulation of innate immunity in healthy 
differentiated cells  
19 9115 PMID:17981789 
Determination of a cell proliferation and chromosomal instability 
signature in anaplastic thyroid carcinoma  
20 11260 PMID:19212673 
Expression profiling of HCC patients with different recurrent free 
survival time  
21 6465 PMID:18490075 Expression data of Hepatocellular Carcinoma  
22 4183 PMID:19461970 
Inflammation adenoma and cancer objective classification of 
colon biopsy specimens with gene expression signature  
23 42109 
 
Identification of anaplastic lymphoma kinase as a candidate of 
new therapeutic target for BCC  
24 14773 PMID:21640118 Roles of EMT regulator in colon cancer  
25 45645 
 
cDNA microarray data after ATP treatment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
